NuVasive expands biologics portfolio to meet clinical and economic needs
NuVasive announced the U.S. commercial launch of three new biologics offerings to include traditional bone allograft, amniotic membrane DS and additional form factors to the current PropelTM DBM product line. September 24, 2018